Zentalis Pharma (ZNTL) a name hitting new highs and an unusual late day trade buys 2000 October $70/$100 call spreads for $5.70. UBS started shares Buy with a $91 target in May citing strong potential across the company’s WEE1, oral SERD, and BCL-2 in solid tumors ahead of key clinical updates from all programs over the next 12-18 months. ZNTL price-strength and a name in an area seeing a lot of M&A makes this an interesting trade.